JNJ Oct 2024 130.000 call
| Previous Close | 35.88 |
| Open | 35.88 |
| Bid | 32.90 |
| Ask | 33.50 |
| Strike | 130.00 |
| Expire Date | 2024-10-18 |
| Day's Range | 35.88 - 35.88 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 1 |
BloombergSanofi Healthcare Bidders Revising Offers Over Talc Concerns
(Bloomberg) -- Bidders for Sanofi’s consumer healthcare unit are revising their offers in part to address concerns around potential liabilities related to a brand that sold talcum powder, according to people with knowledge of the matter. Most Read from BloombergWhat Do US Vehicle Regulators Have Against Tiny Cars?Mexico City Restricts Airbnb Rentals to Curb ‘Gentrification’NYC Schools Reverse Course on Cell-Phone Ban After Parents BalkThe Corner Store ComebackRoofs of Mexico City’s Massive Food
ReutersJ&J discontinues dengue drug study after changes in R&D portfolio
In a separate emailed statement, J&J also said it will also "explore opportunities to advance the clinical development of mosnodenvir outside the company, so that others may build on our research." Six of 10 participants on the drug showed no detectable dengue virus in their blood after being injected with a type of the pathogen, according to data that was presented by J&J in October last year from another mid-stage study. J&J said that efficacy data from the field study will be available once the final data analyses are complete.
- Investing.com
Wells Fargo says there is a risk that Johnson & Johnson will guide lower
Investing.com -- Wells Fargo analysts cautioned that Johnson&Johnson (NYSE:JNJ) may lower its earnings guidance for 2024 when the company reports third-quarter results, despite expectations of stable sales growth.
